Puma Biotechnology (PBYI) Gross Profit (2017 - 2026)

Puma Biotechnology's Gross Profit history runs 10 years deep, the most recent figure standing at $34.4 million for Q1 2026.

• Quarterly Gross Profit fell 2.99% year-over-year to $34.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $169.2 million (changed 0.4% YoY) and the FY2025 annual result came in at $170.2 million, up 2.5% from the prior year.
• Gross Profit was $34.4 million for Q1 2026 at Puma Biotechnology, down from $52.3 million in the prior quarter.
• Across five years, Gross Profit topped out at $70.8 million in Q4 2022 and bottomed at $33.0 million in Q1 2024.
• A 5-year average of $43.4 million and a median of $42.7 million in 2023 frame the typical range for Gross Profit.
• Peak annual rise in Gross Profit reached 62.92% in 2022, while the deepest fall reached 49.15% in 2022.
• Puma Biotechnology's Gross Profit stood at $70.8 million in 2022, then slumped by 32.42% to $47.9 million in 2023, then declined by 5.64% to $45.2 million in 2024, then advanced by 15.88% to $52.3 million in 2025, then plunged by 34.28% to $34.4 million in 2026.
• Business Quant data shows PBYI's Gross Profit at $34.4 million in Q1 2026, $52.3 million in Q4 2025, and $42.3 million in Q3 2025.